Exam 2 - Prostate Cancer Flashcards

1
Q

Most common histology type of prostate cancer

A

adenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Most common site of metastases in prostate cancer

A

Bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment options for localized disease:

A
  1. active surveillance
  2. radiation
  3. surgery

(may add ADT if high risk)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

LHRH agonists acute toxicities

A

tumor flare (metastatic setting), gynecomastia, hot flashes, erectile dysfunction, edema, injection site reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

LHRH agonists long-term toxicities

A

(similar to estrogen deprivation symptoms)
osteoporosis, fractures, obesity, insulin resistance, increased risk of both diabetes and CV events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Anti-androgens toxicities

A

diarrhea, hematuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which anti-androgen is the drug of choice and why?

A

Bicalutamide (Casodex) - long half-life and daily dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the goal level of testosterone after 1 month of using ADT?

A

< 50 ng/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Caution using enzalutamide in patients with history of….

A

Seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Patients need to take prednisone with which anti-androgen drug?

A

Abiraterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which androgen receptor antagonist offers potentially less toxicities than others?

A

Darolutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

For men who at not high-risk, what age should they start prostate cancer screening?

A

50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

If a man’s PSA ≥ 2.5 ng/mL, how often should they get screened?

A

annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

If a man’s PSA < 2.5 ng/mL, how often should they get screened?

A

every 2 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is an important factor in determining what treatment plan the patient receives with m1 disease?

A

low volume vs high volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment options for m0HSPC:

A
  1. observation
  2. ADT
16
Q

Treatment options for m0CRPC:

A

ADT +
Enzalutamide
Apalutamide
Darolutamide

17
Q

Treatment options for m1HSPC low volume:

A

ADT
ADT + abiraterone
ADT + enzalutamide
ADT + apalutamide
Sipuleucel T

18
Q

Treatment options for m1HSPC (high volume):

A

ADT
ADT + abiraterone
ADT + enzalutamide
ADT + docetaxel + abiraterone
ADT + docetaxel + darolutamide

19
Q

Treatment options for m1CRPC:

A

-Genomic testing, dMMR, MSI status
-Continue ADT +
1. Sipuleucel-T
2. Docetaxel
3. Cabazitaxel
4. Radium 223
5. Abiraterone
6. Enzalutamide

20
Q

A patient is receiving ADT with darolutamide, but his PSA is increasing and his scans show bony metastases. If he wants to avoid significant toxicities, what would be the best treatment option?

What would be used to treat his bony metastases?

A

Abiraterone + prednisone

Zoledronic acid

21
Q

Patient presents with high volume disease (diffuse bone and liver metastases). What would be the appropriate treatment for this patient?

A

ADT + docetaxel + abiraterone/darolutamide